Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Manca, Claudia ^a   Koo, Mi Sun ^a   Peixoto, Blas ^a   Fallows, Dorothy ^a   Kaplan, Gilla ^a   Subbian, Selvakumar ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PYRAZINAMIDE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIMYCOBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOST; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG TUBERCULOSIS; MICROARRAY ANALYSIS; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TUBERCULOSIS; UPREGULATION;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATION MEDIATORS; MALE; MICE; MYCOBACTERIUM TUBERCULOSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRAZINAMIDE; TUBERCULOSIS, PULMONARY;

EID: 84883317054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074082     Document Type: Article

References (70)

1. WHO (2012) Tuberculosis Fact Sheet. World Health Organization, Geneva, Switzerland.
2. Mitchison D, Davies G, (2012) The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 16: 724-732.
3. IUATLD (2000) International Union Against Tuberculosis and Lung Diseases, Paris.
4. Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM, (2008) Biomarkers for TB treatment response: challenges and future strategies. J Infect 57: 103-109.
5. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, et al. (2006) Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144: 650-659.
6. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, et al. (2010) Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375: 1920-1937.
7. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, et al. (2002) Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360: 528-534.
8. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, et al. (2009) Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 180: 558-563.
9. Sharma SK, Mohan A, (2004) Extrapulmonary tuberculosis. Indian J Med Res 120: 316-353.
10. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, et al. (2013) Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One 8: e61002.
11. McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, et al. (2012) Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 205Suppl 2: S147-158.
12. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, et al. (2011) CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 184: 972-979.
13. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A, (2011) Immunological biomarkers of tuberculosis. Nat Rev Immunol 11: 343-354.
14. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, et al. (2013) Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 207: 18-29.
15. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G, (2009) Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Exp Immunol 156: 69-77.
16. Riou C, Perez Peixoto B, Roberts L, Ronacher K, Walzl G, et al. (2012) Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One 7: e36886.
17. Mendez S, Traslavina R, Hinchman M, Huang L, Green P, et al. (2009) The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob Agents Chemother 53: 5114-5121.
18. Sinsimer D, Fallows D, Peixoto B, Krahenbuhl J, Kaplan G, et al. (2010) Mycobacterium leprae actively modulates the cytokine response in naive human monocytes. Infect Immun 78: 293-300.
19. Manca C, Tsenova L, Barry CE, (1999) Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 162: 6740-6746.
20. Manca C, Peixoto B, Malaga W, Guilhot C, Kaplan G, (2012) Modulation of the cytokine response in human monocytes by mycobacterium leprae phenolic glycolipid-1. J Interferon Cytokine Res 32: 27-33.
21. Sinsimer D, Huet G, Manca C, Tsenova L, Koo MS, et al. (2008) The phenolic glycolipid of Mycobacterium tuberculosis differentially modulates the early host cytokine response but does not in itself confer hypervirulence. Infect Immun 76: 3027-3036.
22. Koo MS, Manca C, Yang G, O'Brien P, Sung N, et al. (2011) Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One 6: e17091.
23. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, et al. (2012) Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 7: e1002262.
24. Koo MS, Subbian S, Kaplan G, (2012) Strain specific transcriptional response in Mycobacterium tuberculosis infected macrophages. Cell Commun Signal 10: 2.
25. Peloquin CA, (2002) Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62: 2169-2183.
26. Heysell SK, Moore JL, Keller SJ, Houpt ER, (2010) Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 16: 1546-1553.
27. Donald PR, Maritz JS, Diacon AH, (2012) Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb) 92: 1-8.
28. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, et al. (2007) Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 11: 972-978.
29. Conte JE Jr, Golden JA, Duncan S, McKenna E, Zurlinden E, (1999) Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 43: 1329-1333.
30. Heifets L, Higgins M, Simon B, (2000) Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 4: 491-495.
31. Rastogi N, Potar MC, David HL, (1988) Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis. Antimicrob Agents Chemother 32: 287.
32. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, et al. (2007) Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 51: 1011-1015.
33. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, et al. (2009) Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53: 4178-4184.
34. McCune RM Jr, McDermott W, Tompsett R, (1956) The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 104: 763-802.
35. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, et al. (2011) Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 55: 1527-1532.
36. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z, (2003) Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52: 790-795.
37. Zidek Z, (1999) Adenosine- cyclic AMP pathways and cytokine expression. Eur Cytokine Netw 10: 319-328.
38. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M, (2008) Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol 39: 127-132.
39. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, et al. (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 118: 649-658.
40. Souness JE, Aldous D, Sargent C, (2000) Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47: 127-162.
41. Zhang Y, Mitchison D, (2003) The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7: 6-21.
42. Ungerstedt JS, Blomback M, Soderstrom T, (2003) Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 131: 48-52.
43. Campbell PI, Abraham MI, Kempson SA, (1989) Increased cAMP in proximal tubules is acute effect of nicotinamide analogues. Am J Physiol 257: F1021-1026.
44. Shimoyama M, Kawai M, Nasu S, Shioji K, Hoshi Y, (1975) Inhibition of adenosine 3',5'-monophosphate phosphodiesterase by nicotinamide and its homologues in vitro. Physiol Chem Phys 7: 125-132.
45. Li AC, Glass CK, (2004) PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45: 2161-2173.
46. Zhang Y, Jiang Z, Su Y, Chen M, Li F, et al. (2012) Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats. J Appl Toxicol.
47. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S, (2002) Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther 302: 18-25.
48. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA, (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410.
49. Delerive P, Fruchart JC, Staels B, (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169: 453-459.
50. Chinetti G, Fruchart JC, Staels B, (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49: 497-505.
51. Jiang C, Ting AT, Seed B, (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
52. Youssef J, Badr M, (2004) Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. J Biomed Biotechnol 2004: 156-166.
53. Clark RB, (2002) The role of PPARs in inflammation and immunity. J Leukoc Biol 71: 388-400.
54. Poynter ME, Daynes RA, (1998) Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273: 32833-32841.
55. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK, (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82.
56. Michalik L, Wahli W, (1999) Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol 10: 564-570.
57. Rajaram MV, Brooks MN, Morris JD, Torrelles JB, Azad AK, et al. (2010) Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. J Immunol 185: 929-942.
58. Mahajan S, Dkhar HK, Chandra V, Dave S, Nanduri R, et al. (2012) Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARgamma and TR4 for survival. J Immunol 188: 5593-5603.
59. Kim JJ, Lee HM, Shin DM, Kim W, Yuk JM, et al. (2012) Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe 11: 457-468.
60. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, et al. (2008) Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456: 264-268.
61. Harris J, (2011) Autophagy and cytokines. Cytokine 56: 140-144.
62. Yuhas Y, Berent E, Ovadiah H, Azoulay I, Ashkenazi S, (2006) Rifampin augments cytokine-induced nitric oxide production in human alveolar epithelial cells. Antimicrob Agents Chemother 50: 396-398.
63. Ziglam HM, Daniels I, Finch RG, (2004) Immunomodulating activity of rifampicin. J Chemother 16: 357-361.
64. Araujo FG, Slifer TL, Remington JS, (2002) Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Clin Microbiol Infect 8: 26-30.
65. Melhus A, (2001) Effects of amoxicillin on the expression of cytokines during experimental acute otitis media caused by non-typeable Haemophilus influenzae. J Antimicrob Chemother 48: 397-402.
66. Dalhoff A, Shalit I, (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3: 359-371.
67. Pahlevan AA, Wright DJ, Bradley L, Smith C, Foxwell BM, (2002) Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J Antimicrob Chemother 49: 531-534.
68. Gil D, Garcia LF, Rojas M, (2003) Modulation of macrophage apoptosis by antimycobacterial therapy: physiological role of apoptosis in the control of Mycobacterium tuberculosis. Toxicol Appl Pharmacol 190: 111-119.
69. Weiss T, Shalit I, Blau H, Werber S, Halperin D, et al. (2004) Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother 48: 1974-1982.
70. Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N, et al. (2002) Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother 46: 2442-2449.